In colorectal, pancreatic, and breast cancers, and in cell/adenosquamous carcinoma of the gallbladder, increased expression of CDH3 was significantly associated with progression markers such as cell differentiation, tumor size, lymph node infiltration, and outcome of surgical intervention, and a reduction in overall survival, thus indicating that CDH3 appears to act in a context-dependent manner as either a tumor suppressive or oncogenic factor in different carcinomas [21,22,27,37]. The gene discussed is CDH3; the disease is breast cancer.